Doxorubicin-induced cardiomyopathy: gene variant TRPC6 as therapeutic target

Back

HFA Premium Access

Doxorubicin-induced cardiomyopathy: gene variant TRPC6 as therapeutic target

Session: Young Investigator Award - Basic Science and Translational Science

Topic: Cardio-Oncology

Speaker: Doctor K. Bruno (Jacksonville, US)

Event: Heart Failure 2019

Congress Presentation

Add to my library

About the speaker

Doctor Katelyn Bruno

Mayo Clinic, Jacksonville (United States of America)

0 follower

5 more presentations in this session

GRK2 regulates the endothelial responsiveness to bradykinin: role in human angioedema

Speaker: Doctor J. Gambardella (Napoly, IT)

Empaglifozin has cardioprotective and anti-inflammatory effects in mice during doxorubicin treatment

Speaker: Doctor V. Quagliariello (Naples, IT)

Sterol metabolism is differentially regulated in human induced pluripotent stem cell-derived cardiomyocytes of peripartum cardiomyopathy patients

Speaker: Mr M. Hoes (Maastricht, NL)

Gut microbiota composition and interactions with diet: dysbiosis in heart failure is partly related to lower fiber intake

Speaker: Ms C. Mayerhofer (Oslo, NO)

Access

Abstract

Diastolic function modulation via protein kinase G-dependent Ca2(+)/calmodulin-dependent protein kinase-II phosphorylation and oxidation

Speaker: Ms M. Herwig (Bochum, DE)

Access

Abstract

Access the full session

Young Investigator Award - Basic Science and Translational Science

Speakers: Doctor K. Bruno, Doctor J. Gambardella, Doctor V. Quagliariello, Mr M. Hoes, Ms C. Mayerhofer...

Access

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources